ArticleCell reports. Medicine2021

Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.

Hui-Wen Lue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.